Administração transdérmica de cloridrato de raloxifeno encapsulado em nanopartículas lipídicas: estudos de pré-formulação para seleção dos lipídeos e tensoativos
Nenhuma Miniatura disponível
Data
2017-09-26
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Goiás
Resumo
Introduction: Raloxifene hydrochloride (RLX) is a widely prescribed drug for the treatment of osteoporosis and breast cancer. However, RLX presents a low oral bioavailability (2%), being an excellent candidate for transdermal drug delivery. The aim of this work was to develop nanostructured lipid carriers (NLC) containing RLX for transdermal drug delivery. In order to choose proper excipients, a compatibility study was performed. Methodology: Compatibility study was performed with differential scanning calorimeter (DSC), thermogravimetric anaysis (TGA), derivative thermogravimetry (DTG), isothermal stress testing (IST) and solubility study. RLX quantification was performed by high performance liquid chromatography (HPLC). After choosing the excipients, CLN were obtained by the microemulsion technique. Characterization was performed for mean diameter, polidispersivity index (PdI), zeta potential, entrapment efficiency (EE%) and stability. In vitro release and permeation studies were performed in Franz diffusion cells. Results and discussion. Conclusions: Drug-excipient compatibility studies allowed the development of stable and monodisperse CLN, capable of controlling drug release and increase its permeation in the skin when compared to the non-encapsulated drug in the control formulation.
Descrição
Citação
ALVES, G. L. Administração transdérmica de cloridrato de raloxifeno encapsulado em nanopartículas lipídicas: estudos de pré-formulação para seleção dos lipídeos e tensoativos. 2017. 108 f. Dissertação (Mestrado em Ciências Farmacêuticas) - Universidade Federal de Goiás, Goiânia, 2017.